Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, Montpellier Cedex, France.
Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular & Functional Enzymology, Paris, France.
Med Res Rev. 2018 Mar;38(2):655-683. doi: 10.1002/med.21451. Epub 2017 Jun 13.
Kallikrein-related peptidases (KLKs) are a family of 15 secreted serine proteases that are involved in various physiological processes. Their activities are subtly regulated by various endogenous inhibitors, ranging from metallic ions to macromolecular entities such as proteins. Furthermore, dysregulation of KLK activity has been linked to several pathologies, including cancer and skin and inflammatory diseases, explaining the numerous efforts to develop KLK-specific pharmacological inhibitors as potential therapeutic agents. In this review, we focus on the huge repertoire of KLKs inhibitors reported to date with a special emphasis on the diversity of their molecular mechanisms of inhibition.
激肽释放酶相关肽酶(KLKs)是一族 15 种分泌型丝氨酸蛋白酶,参与多种生理过程。其活性受到各种内源性抑制剂的精细调节,范围从金属离子到蛋白质等大分子物质。此外,KLK 活性的失调与多种病理有关,包括癌症以及皮肤和炎症性疾病,这解释了人们为开发 KLK 特异性药理抑制剂作为潜在治疗剂而进行的大量努力。在这篇综述中,我们重点介绍了迄今为止报道的大量 KLK 抑制剂,特别强调了它们抑制机制的多样性。